Nearly 20,000 women in a recent study took either tamoxifen, the only drug currently approved to reduce breast cancer incidence in high-risk women, or the osteoporosis drug raloxifene (Evista) daily for five years.

Result: Both drugs cut invasive breast cancer incidence by 50%. However, the raloxifene group developed 36% fewer uterine cancers and 29% fewer blood clots than the tamoxifen group.

Theory: Like tamoxifen, raloxifene helps moderate the hormone estrogen, but with fewer side effects. Raloxifene received FDA approval in September 2007 for breast cancer prevention.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in